In recent years, there has been an increasing focus on investigating the role of Tau in the onset and progression of Alzheimer’s Disease (AD), and in other neurodegenerative diseases associated with the accumulation of pathological misfolded Tau, such as progressive supranuclear palsy (PSP) and frontotemporal lobar degeneration (FTLD). Studies using recently introduced second-generation Tau tracers suggests that these tracers are binding to Tau with higher specificity compared to previous tracers, leading to increased interest in Tau within clinical studies. However, it’s still unclear what role Tau imaging will play in clinical trials: should Tau be used as a clinical endpoint; and how does it link to other biomarkers such as amyloid-beta, with some studies suggesting that amyloid-beta triggers the spread of Tau beyond the MTL region.
Given that the majority of Tau studies have been conducted using first-generation PET tracers, which had shown high incidences of off-site binding, it will be important to review the current data to understand what we know about Tau in AD and how second-generation tracers are being applied in clinical studies. Additionally, this webinar will cover the steps being taken to advance Tau PET operational and analytical methodologies in AD clinical studies and other Tau-related neurodegenerative diseases.
- Victor L. Villemagne, Associate Professor, Department of Medicine, Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne
- Richard Manber, Biomarker Scientist, IXICO
The spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited progressive ataxia disorders. SCA Global is a worldwide initiative for clinical research in SCAs and provides a flexible and open research platform to pursue the following goals: 1. To better understand the manifestation, evolution and impact of the various SCAs, 2. To develop and validate biomarkers which can be used in future interventional trials, 3. To facilitate access to people with SCAs who are willing to participate in clinical trials.
The AAT-AD/PD™ Focus Meeting 2020 will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
A central theme will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers discussed in the sessions and corridors at AD/PD™ 2019, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.
The 1st conference of the ARCA Global network aims to advance a global consortium for translational studies in autosomal-recessive ataxias (ARCAs), ARCA Global. ARCA Global is a dynamic, collaborative translational research initiative ultimately aiming to prepare and conduct harmonized multi-center treatment trials in genetically stratified ARCAs, thus allowing to translate the recent progress in ARCA genetics directly into stringent targeted treatment trials. It will integrate all main stakeholder groups including basic and clinician scientists, industry, and patient organizations.
Over the course of four stimulating days of in-depth discussions in 20 different conferences, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including: Site Selection and Management, Patient Engagement, Recruitment and Retention, Protocol Optimization, Feasibility, Data Strategy and Analytics, Sensors and Wearables, Artificial Intelligence, Clinical Biomarker Strategy, Precision Medicine, Clinical Biomarkers, and an all new track on Medical Device Clinical Trial Operations and Regulations.
HAI 2020 will continue to emphasize ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily spring from brief presentations by active investigators who will report on unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
The program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover, there are panels on innovation in NeuroTech covering banking, device, diagnostics and software. The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma, biotech and medtech companies.
The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
The International Ataxia Research Conference will be a comprehensive scientific review of new research into ataxias, covering topics from the molecular basis of disease to potential therapeutic treatments and clinical trials. The conference will include Friedreich’s ataxia and other recessive ataxias (e.g. ataxia with oculomotor apraxia), dominant ataxias (e.g. spinocerebellar ataxias, DRPLA, episodic ataxias) and autoimmune ataxias. The meeting is aimed at academic, clinical and industry researchers with an interest in ataxia research and drug development.
1-10 of 25 results